Ipsen: Neuroendocrine Tumors trials

The registry lists 29 Neuroendocrine Tumors studies with Ipsen as lead sponsor. 1 are open to participants now and 10 have results posted.

Phase 1 2Phase 2 7Phase 3 2Phase 4 2No phase 18(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior TreatmentRecruitingNCT07314164
• Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Phase 3Results posted
• To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)CompletedNCT03220217Phase 2Results posted
• Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.CompletedNCT02698410Phase 2Results posted
• Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine TumoursTerminatedNCT02683941Phase 3Results posted
• Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mgCompletedNCT02651987Phase 2Results posted
• Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETsTerminatedNCT02592707Phase 1/2Results posted
• Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NETCompletedNCT02231762Phase 2Results posted
• 68Ga-OPS202 Study for Diagnostic Imaging of GEP NETCompletedNCT02162446Phase 1/2Results posted
• Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours PatientsCompletedNCT02075606Phase 4Results posted
• Somatuline Autogel Preference and Health Economy StudyCompletedNCT00681187Phase 4Results posted
• A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and AcromegalyCompletedNCT06253897
• A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NETTerminatedNCT05922579
• United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration SettingCompletedNCT04649580
• Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.TerminatedNCT03947762
• Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical PracticeWithdrawnNCT03895463
• Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide AutogelCompletedNCT03562091
• Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in SpainCompletedNCT03220087
• Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine TumorsCompletedNCT03112694
• Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)CompletedNCT03017690
• Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine TumoursCompletedNCT02853422
• A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine TumoursTerminatedNCT02788578
• Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine TumoursCompletedNCT02788565
• Community-based Neuroendocrine Tumor (NET) Research StudyCompletedNCT02730104
• Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETsCompletedNCT02630654
• Somatuline Predictive Factors in Acromegaly and NETCompletedNCT01840449
• A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of DiarrheaCompletedNCT01234168
• Non Interventional Post Marketing Programme in Neuroendocrine TumoursCompletedNCT00747786
• Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine TumoursCompletedNCT00326469Phase 2